These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 33693664)

  • 1. Reduced Trypanosoma cruzi-specific humoral response and enhanced T cell immunity after treatment interruption with benznidazole in chronic Chagas disease.
    Castro Eiro MD; Natale MA; Alvarez MG; Shen H; Viotti R; Lococo B; Bua J; Nuñez M; Bertocchi GL; Albareda MC; Cesar G; Tarleton RL; Laucella SA
    J Antimicrob Chemother; 2021 May; 76(6):1580-1592. PubMed ID: 33693664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in the immune response after treatment with benznidazole versus no treatment in patients with chronic indeterminate Chagas disease.
    Vallejo A; Monge-Maillo B; Gutiérrez C; Norman FF; López-Vélez R; Pérez-Molina JA
    Acta Trop; 2016 Dec; 164():117-124. PubMed ID: 27619190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial.
    Morillo CA; Waskin H; Sosa-Estani S; Del Carmen Bangher M; Cuneo C; Milesi R; Mallagray M; Apt W; Beloscar J; Gascon J; Molina I; Echeverria LE; Colombo H; Perez-Molina JA; Wyss F; Meeks B; Bonilla LR; Gao P; Wei B; McCarthy M; Yusuf S;
    J Am Coll Cardiol; 2017 Feb; 69(8):939-947. PubMed ID: 28231946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection).
    Vallejo M; Reyes PP; Martinez Garcia M; Gonzalez Garay AG
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD004102. PubMed ID: 33305846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy.
    Laucella SA; Mazliah DP; Bertocchi G; Alvarez MG; Cooley G; Viotti R; Albareda MC; Lococo B; Postan M; Armenti A; Tarleton RL
    Clin Infect Dis; 2009 Dec; 49(11):1675-84. PubMed ID: 19877967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B-Cell Responses in Chronic Chagas Disease: Waning of Trypanosoma cruzi-Specific Antibody-Secreting Cells Following Successful Etiological Treatment.
    Cesar G; Natale MA; Albareda MC; Alvarez MG; Lococo B; De Rissio AM; Fernandez M; Castro Eiro MD; Bertocchi G; White BE; Zabaleta F; Viotti R; Tarleton RL; Laucella SA
    J Infect Dis; 2023 May; 227(11):1322-1332. PubMed ID: 36571148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of benznidazole treatment on the functional response of Trypanosoma cruzi antigen-specific CD4+CD8+ T cells in chronic Chagas disease patients.
    Pérez-Antón E; Egui A; Thomas MC; Puerta CJ; González JM; Cuéllar A; Segovia M; López MC
    PLoS Negl Trop Dis; 2018 May; 12(5):e0006480. PubMed ID: 29750791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations.
    Garcia S; Ramos CO; Senra JF; Vilas-Boas F; Rodrigues MM; Campos-de-Carvalho AC; Ribeiro-Dos-Santos R; Soares MB
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1521-8. PubMed ID: 15793134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies.
    Sguassero Y; Cuesta CB; Roberts KN; Hicks E; Comandé D; Ciapponi A; Sosa-Estani S
    PLoS One; 2015; 10(10):e0139363. PubMed ID: 26436678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial.
    Torrico F; Gascon J; Ortiz L; Alonso-Vega C; Pinazo MJ; Schijman A; Almeida IC; Alves F; Strub-Wourgaft N; Ribeiro I;
    Lancet Infect Dis; 2018 Apr; 18(4):419-430. PubMed ID: 29352704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease.
    Rial MS; Scalise ML; Arrúa EC; Esteva MI; Salomon CJ; Fichera LE
    PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006119. PubMed ID: 29267280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benznidazole therapy in Trypanosoma cruzi-infected mice blocks thymic involution and apoptosis of CD4+CD8+ double-positive thymocytes.
    Olivieri BP; Farias-De-Oliveira DA; Araujo-Jorge TC; Cotta-de-Almeida V
    Antimicrob Agents Chemother; 2005 May; 49(5):1981-7. PubMed ID: 15855522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of Benznidazole in Experimental Chronic Chagas Disease Using the Swiss Mouse-Berenice-78 Trypanosoma cruzi Strain Model.
    de Jesus SM; Pinto L; Moreira FL; Nardotto GHB; Cristofoletti R; Perin L; Fonseca KDS; Barbêdo P; Bandeira LC; Vieira PMA; Carneiro CM
    Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33168611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Scheme of Intermittent Benznidazole Administration in Patients Chronically Infected with Trypanosoma cruzi: Clinical, Parasitological, and Serological Assessment after Three Years of Follow-Up.
    Álvarez MG; Ramírez JC; Bertocchi G; Fernández M; Hernández Y; Lococo B; Lopez-Albizu C; Schijman A; Cura C; Abril M; Laucella S; Tarleton RL; Natale MA; Castro Eiro M; Sosa-Estani S; Viotti R
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32571827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological exhaustion and functional profile of CD8
    Pérez-Antón E; Egui A; Thomas MC; Simón M; Segovia M; López MC
    Acta Trop; 2020 Feb; 202():105242. PubMed ID: 31669531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study.
    Perez-Mazliah DE; Alvarez MG; Cooley G; Lococo BE; Bertocchi G; Petti M; Albareda MC; Armenti AH; Tarleton RL; Laucella SA; Viotti R
    J Antimicrob Chemother; 2013 Feb; 68(2):424-37. PubMed ID: 23104493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection.
    de Andrade AL; Zicker F; de Oliveira RM; Almeida Silva S; Luquetti A; Travassos LR; Almeida IC; de Andrade SS; de Andrade JG; Martelli CM
    Lancet; 1996 Nov; 348(9039):1407-13. PubMed ID: 8937280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update on benznidazole for the treatment of patients with Chagas disease.
    Thakare R; Dasgupta A; Chopra S
    Drugs Today (Barc); 2018 Jan; 54(1):15-23. PubMed ID: 29569658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of Trypanosoma cruzi-specific T-cell responses after chemotherapy for chronic Chagas disease.
    Albareda MC; Laucella SA
    Mem Inst Oswaldo Cruz; 2015 May; 110(3):414-21. PubMed ID: 25993507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Memory impairment in chronic experimental Chagas disease: Benznidazole therapy reversed cognitive deficit in association with reduction of parasite load and oxidative stress in the nervous tissue.
    Vilar-Pereira G; Castaño Barrios L; Silva AAD; Martins Batista A; Resende Pereira I; Cruz Moreira O; Britto C; Mata Dos Santos HA; Lannes-Vieira J
    PLoS One; 2021; 16(1):e0244710. PubMed ID: 33400707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.